SCHEMBL5661986

SCHEMBL5661986

OCCCN1CCN(CCN2CCOCC2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.71
KDM4E B2RXH2 2/20 0.71
KEAP1 Q14145 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HPGD P15428 1/20 0.52
DUSP3 P51452 1/20 0.52
GLA P06280 1/20 0.47
GAA P10253 1/20 0.46
SIGMAR1 Q99720 2/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 2/20 0.44
USP2 O75604 1/20 0.43
MAPK1 P28482 2/20 0.42
PAOX Q6QHF9 1/20 0.42
HIF1A Q16665 1/20 0.42
CYP1A2 P05177 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
HTR2A P28223 1/20 0.42
SCN1A P35498 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8458 0.98 ALDH1A1 (0.67) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL516842 0.95 ALDH1A1 (0.64) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL22609104 0.93 ALDH1A1 (0.75) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL11087 0.91 KDM4E (0.64) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL19617043 0.89 ALDH1A1 (0.57) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL12014338 0.88 KDM4E (0.61) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL1404044 0.88 KDM4E (0.61) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL4027543 0.88 KDM4E (0.61) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL12014339 0.88 KDM4E (0.61) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD
SCHEMBL12014335 0.88 KDM4E (0.61) ALDH1A1KDM4EKEAP1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070088044-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB 2007-04-19 US disclosed
US-20050054662-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-03-10 US disclosed
EP-1444211-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2004-08-11 EP disclosed
WO-2003040109-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054662-A1 Quinazoline derivatives as antitumor agents ERBB2, ERBB3, ABL1 ALDH1A1 3334/4885KDM4E 2435/4885KEAP1 539/4885
US-20070088044-A1 Quinazoline derivatives as antitumor agents ERBB2, EGFR, ERBB4 ALDH1A1 4094/4885KDM4E 2238/4885KEAP1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.